SSG
MLTX icon

Summit Securities Group’s MoonLake Immunotherapeutics MLTX Stock Holding History

Summit Securities Group’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-516
Closed -$9.62K – 1295
2026
Q1 		$9.62K Buy
+516
New +$8.55K ﹤0.01% 677
2024
Q4 		– Sell
-90
Closed -$5K – 804
2024
Q3 		$5K Buy
+90
New +$4.22K ﹤0.01% 426

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Summit Securities Group's MLTX Position: Q2 2026 in Review

Summit Securities Group sold out of MoonLake Immunotherapeutics (MLTX) in Q2 2026, closing a stake of 516 shares — an estimated $9.62K sold.

Summit Securities Group first reported a position in MLTX in Q3 2024 and held it in 2 quarters. The position peaked at $9.62K in Q1 2026. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • Summit Securities Group reported no remaining MoonLake Immunotherapeutics position as of Q2 2026 after selling out during the quarter.
  • Summit Securities Group sold 516 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $9.62K.
  • Summit Securities Group first reported a position in MoonLake Immunotherapeutics in Q3 2024 and held it in 2 quarters.
  • Summit Securities Group's MoonLake Immunotherapeutics position peaked at $9.62K in Q1 2026.
  • 173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Summit Securities Group's 13F filing for Q2 2026, filed 3 Aug 2026.